Qishenyiqi dripping pills
Phase 3Small molecule
Qishenyiqi dripping pills is one of 70 small molecule programs targeting Myocardial Infarction. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
89 competitors in Myocardial Infarction
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Adenocard
AstellasApproved
Neoral
NovartisApproved
Aldactone
PfizerApproved
Niacor
AbbVieApproved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Alka-Seltzer
AAbbott
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Epsom Salt
FFresenius Kabi USA, LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Qishenyiqi dripping pills. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details